|Podcasts|April 15, 2021

Episode 80: Rugby Rules in Pharma

John Furey, CEO of Imvax and an Editorial Advisory Board member for Pharm Exec, discusses some leadership principles he learned while playing rugby as a young man in Ireland, and how those tenets can translate to the C-suite.

John Furey, CEO of Imvax and a member of the Pharm Exec Editorial Advisory Board, talks about his background playing rugby and the essential leadership lessons he’s gleaned from the sport.

You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.


Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.